Studies have demonstrated that different molecular subtypes of breast cancer, such as luminal A (LUMA), luminal B (LUMB), HER2-enriched, and triple-negative breast cancers (TNBC) present distinct clinical behaviors, have different prognoses and require personalized treatment approaches [11, 18–20]. The gene discussed is ERBB2; the disease is breast carcinoma.